The Oral Insulin market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are taken orally to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Insulin is a relatively new form of treatment, and is seen as a more convenient and less invasive alternative to traditional insulin injections. It is also seen as a potential solution to the problem of poor adherence to insulin therapy. Oral Insulin is still in the early stages of development, and there are currently no approved oral insulin products on the market. However, several companies are researching and developing oral insulin products, and some have already completed clinical trials. Companies in the Oral Insulin market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
